This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks to Watch for Earnings on Aug 3
by Zacks Equity Research
MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.
Earnings Preview: Organon (OGN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
Cano Health, Inc. (CANO) Stock Jumps 17.1%: Will It Continue to Soar?
by Zacks Equity Research
Cano Health, Inc. (CANO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Investors Should Retain Charles River (CRL) Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable collaborations.
Charles River (CRL) Signs saRNA-Based Vaccine Manufacture Deal
by Zacks Equity Research
Charles River's (CRL) industry knowledge in plasmid DNA production will benefit Ziphius Vaccines' early-stage saRNA manufacturing program.
Charles River (CRL) Prospers Internationally Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Why Is Charles River (CRL) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Charles River Laboratories (CRL) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Retain Charles River (CRL) Stock for Now
by Zacks Equity Research
Investors are optimistic about Charles River (CRL) due to the strong first-quarter results.
Charles River (CRL) DSA Arm Prospers, Currency Headwind Stays
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 1.48% and 0.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MedTech Stocks' Q1 Earnings Due on May 4: CRL, IDXX & NUVA
by Urmimala Biswas
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how CRL, IDXX and NUVA fare this time.
Charles River Laboratories (CRL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River (CRL) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Robust global demand for the research model and multiple initiatives to expedite the discovery process are likely to have contributed to Charles River's (CRL) first-quarter results.
Charles River (CRL) Buys Explora BioLabs to Expand in CRO Space
by Zacks Equity Research
Explora BioLabs' business is likely to complement and expand the Charles River's (CRL) CRADL operation within the broader Insourcing Solutions business.
Here's Why You Should Retain Charles River (CRL) Stock For Now
by Zacks Equity Research
Investors are optimistic about Charles River's (CRL) strong segmental growth and notable partnerships.
Charles River Laboratories (CRL) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Charles River (CRL) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Charles River (CRL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Inflation Beneficiary ETFs in Focus as Prices Soar
by Neena Mishra
These ETFs invests in assets that benefit from inflation